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Abstract
Type 2 diabetes mellitus is widely prevalent and is
often coexistent with obesity. Many of the available
treatment options have side effects such as weight
gain which often affect patient’s willingness to
continue the treatment. Effective weight loss, lack of
significant hypoglycaemia, and favourable
cardiometabolic profile make Incretin based therapies
an attractive treatment option for type 2 diabetes.
Incretin based therapies are available as either incretin
mimetics (also called GLP-1 agonists) or incretin
enhancers (DPP-4 inhibitors). Although agents in both
these classes of incretin based therapy are effective
through a common GLP-1 pathway, there are many
differences amongst them including the route of
administration, frequency of administration, effects on
body weight, extent of glycaemic improvement. There
are several trials evaluating these individual incretin
based agents either as monotherapy or in
combination with other anti-diabetic agents, however
very few have looked into direct comparison amongst
the agents in these two classes. This review is aimed
to look at important mechanistic differences between
incretin mimetics and enhancers through direct
comparison trials and impact of these differences on
biochemical, metabolic and patient satisfaction
parameters.
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The prevalence of type-2 diabetes mellitus (T2DM) is
rapidly increasing worldwide. The International Diabetes
Federation (IDF) estimates the current prevalence of dia-
betes at around 366 million which is estimated to increase
to 552 million cases of diabetes and 398 million cases of
impaired glucose tolerance (IGT) by 2030 [1]. Similarly,
there has been an uptrend in adiposity worldwide [2]. The
National Obesity Observatory data estimates the preva-
lence of obesity in the UK at 23%, while 61% of adults are
overweight [3]. The majority of patients with T2DM are
obese [4] and many of the current therapeutic options for
management of T2DM can cause further weight gain
[5,6]. Concerns about weight gain adversely affect patients’
willingness to begin and continue treatment with glucose-
lowering medications, such as thiazolidinediones (TZDs),
insulin, and sulfonylureas (SU) [7]. Often the patient’s
quality of life can be negatively affected by the underlying
disease process and its complications, such as polyphar-
macy, weight gain, hypoglycemia and micro- and macro-
vascular complications [8]. Recently introduced incretin
based therapies appear to offer advantages over conven-
tional therapies by either keeping the weight steady or
even achieving weight loss and limiting hypoglycemia,
while achieving effective glycemic control. This review
examines the comparisons between two classes of incretin
based therapies, dipeptidyl peptidase 4 (DPP-4) inhibitors
(incretin enhancers) and glucagon-like peptide 1 (GLP-1)
agonists (incretin mimetics). Although use of incretin
based therapies for T2DM has been reviewed before
[9-11], this article focuses on data from head to head
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comparative trials analyzing efficacy, tolerability and safety
profiles between the agents from these two classes.
Physiology of incretins
The classic ‘incretin effect’ refers to the observation that
oral glucose elicits a higher insulin response compared to
intravenous glucose at similar plasma glucose concentra-
tions. GLP-1 and glucose-dependent insulinotropic poly-
peptide (GIP), two major incretin hormones that are
secreted into the circulation by ‘L’ and ‘K’ cells of the small
intestine, respectively, are responsible for 50% to 70% of
glucose dependent insulin release [12-14]. Apart from insu-
linotropic effects, GLP-1 also suppresses glucagon release,
reduces hepatic gluconeogenesis, delays gastric emptying
and reduces food intake by promoting satiety [15]. The
impaired incretin effect in patients with T2DM is thought
to be multifactorial. Reduced postprandial GLP-1 response
[16,17] and a reduced insulinotropic response [18] are con-
tributing factors. In a study comparing healthy subjects
with patients with T2DM, lack of the incretin effect, in
spite of comparable GLP-1 as well as GIP secretion, was
observed [19]. Administration of GLP-1 subcutaneously
over six weeks in patients with T2DM has been shown to
improve glycemic control, insulin sensitivity, and beta cell
function along with reduced gastric emptying and reduc-
tion in bodyweight [15]. However, GLP-1 secretion is not
always reduced and may be normal in patients with T2DM
[20,21]. Age, body weight, fasting glucagon and Non-Esteri-
fied Fatty Acids (NEFA) concentrations are some of the
factors thought to affect the incretin response [21].
Incretin based therapies
Due to various favorable cardiometabolic and insulinotro-
pic effects, GLP-1 is a very attractive candidate as a thera-
peutic invention in management of T2DM. Native GLP-1
has a very short half-life of a few minutes as it is broken
down by endopeptidase enzymes such as DPP-4 which has
a ubiquitous presence in the human body [22-24]. As the
native GLP-1 molecule is unsuitable for routine clinical
use, stimulation of GLP-1 receptors either by administra-
tion of GLP-1 agonists or restoring the endogenous GLP-
1 pool by inhibiting its DPP-4 mediated breakdown are
the two approaches used to obtain or maintain high levels
of GLP-1[14].
Incretin mimetics
GLP-1 agonists mimicking endogenous GLP-1 in their
pharmacokinetic and pharmacological properties are
termed incretin mimetics. These are modified GLP-1
molecules and are resistant to DPP-4 induced degradation.
Exenatide, a molecule originally isolated from the saliva of
the Heloderma suspectum lizard (Exendin-4) was the first
GLP-1 agonist to become available for clinical use and was
approved by the US Food and Drug Administration (FDA)
in April 2005 and by the European Medicine Agency
(EMA) in November 2006 [25,26].
Liraglutide is the first human GLP-1 analogue with 97%
amino acids sequence homology with native GLP-1; fatty
chain addition to its molecule prolongs its half-life to 13
hours [27]. Recently, a long acting once weekly prepara-
tion of exenatide (Bydureon) at a dose of 2 mg has been
approved for clinical use by the EMA in Europe [28].
Incretin enhancers
DPP-4 inhibitors are termed incretin enhancers as they
prolong the half-life and availability of endogenous GLP-1
by inhibiting DPP-4. Sitagliptin was the first DPP-4 inhibi-
tor approved for clinical use in October 2006 followed by
vildagliptin in Europe and saxagliptin in the US markets
[29]. Alogliptin has market approval in Japan, while lina-
gliptin has recently gained approval for clinical use in the
US as well as Europe.
Currently, other GLP-1 agonists (for example, lixisenatide
and albiglutide) and DPP-4 inhibitors are at various stages
of development and in clinical trials programs. Taspoglutide
is another once weekly human GLP-1 analogue in develop-
ment but further trials have been suspended in the late
stages due to agent specific hypersentivity reactions.
Comparisons between incretin mimetics (GLP-1 agonists)
and incretin enhancers (DPP-4 inhibitors)
Agents in both these classes have been studied as mono-
therapy or in combination with other anti-diabetic medi-
cations. DPP-4 inhibitors are administered orally, once a
day as compared to GLP-1 agonists which are adminis-
tered subcutaneously, once or twice a day or more recently
once a week. GLP-1 agonists slow gastric emptying in
addition to a reduction in appetite but DPP-4 inhibitors
do not seem to have these effects [30]. In general, the
observation is that GLP-1 agonists have been found to be
more effective in glycemic management and weight reduc-
tion compared to DPP-4 inhibitors. However, there are a
limited number of head to head studies directly comparing
the effects of DPP-4 inhibitors and GLP-1 agonists. The
first data suggesting key differences between DPP-4 inhibi-
tors and GLP-1 agonists comes from an initial short term
proof of concept study suggesting important mechanistic
differences between exenatide twice a day (bid) and sita-
gliptin [31]. Since then, longer term randomized control
trials (RCTs) have compared these two classes of thera-
peutic agents as summarized in Table 1.
The ‘proof of concept’ study
In a short double blind, double dummy, cross-over study
involving 61 patients with metformin treated T2DM, a two-
week therapy with exenatide (5 mcg bid for the first week,
increasing to 10 mcg bid for the second week) was asso-
ciated with greater improvement in two-hour postprandial
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glucose (PPG) as compared to that obtained with two
weeks of therapy with sitagliptin 100 mg once daily [31].
More importantly, sitagliptin-treated patients noticed
further improvement in PPG levels after changing over to
exenatide suggesting the superiority of exenatide in improv-
ing postprandial hyperglycemia, an effect of increased post-
prandial insulin release associated with GLP-1 receptor
agonists. There was no statistically significant difference in
the improvement achieved by both agents in fasting plasma
glucose (FPG). The differential mechanistic effects are sum-
marized in Table 2.
Patients’ gastric emptying rates were also assessed using
1,000 mg of an oral liquid acetaminophen preparation.
Exenatide significantly slowed gastric emptying compared
to sitagliptin (P =<0.0001). Exenatide-treated patients were
also found to exhibit a reduction in their calorie intake as
assessed by ad libitum meals. There was reduced calorie
intake averaging 134 kcal less in the exenatide-treated
group compared to the sitagliptin-treated group. Due to
the variability of the calorie intake, median caloric intake
was assessed which showed a similar trend (exenatide:
-138 kcal versus sitagliptin: +63 kcal).
During this two-week trial the mean postprandial gluca-
gon concentration relative to baseline was reduced in both
treatment groups; the reduction in postprandial glucagon
following exenatide was significantly greater compared
to sitagliptin (P =<0.0011). There was an increase in the
insulinogenic index of insulin secretion with exenatide
compared to sitagliptin (ratio exenatide to sitagliptin: 1.50
+/- 0.26, P = 0.0239). Nausea was the predominant side
effect, experienced by 34% of patients treated with exena-
tide and 12% of patients treated with sitagliptin. Vomiting
was experienced by 24% of patients treated with exenatide
and 3% of patients treated with sitagliptin [31].
Table 1 Overview of head to head comparisons amongst GLP-1 analogues and DPP-4 inhibitors.




4 weeks Double blind, double
dummy, cross over
Exenatide 5 mcg twice daily for 1st week followed by




Berg et al. [32] 8 weeks Double blind, double
dummy, cross over





26 weeks Open label parallel group Liraglutide 1.2 mg and Liraglutide 1.8 mg Sitagliptin 100 mg
once daily
Metformin
DURATION 2 [35] 26 weeks Double dummy Exenatide QW 2 mg once weekly Sitagliptin 100 mg
once daily
Metformin
DURATION 4 [37] 26 weeks Double dummy Exenatide QW 2 mg once weekly Sitagliptin 100 mg
once daily
none





52 weeks Open label parallel group Exenatide 10 mcg twice daily Sitagliptin 100 mg
once daily
Metformin
DDP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1
Table 2 Mechanistic differences between GLP-1 agonist exenatide and DPP-4 inhibitor sitagliptin [31].
Sitagliptin Exenatide Significance
Change in FPG (mmol/l) 1.04+/- 0.2 0.83+/-0.2 P = 0.3234
Change in PPG (mmol/l) 2.0 +/-0.3 6.26+/-0.3 P <0.0001*
Insulinogenic index Yes Yes- significantly more than sitagliptin P = 0.0239*
Acute Insulin secretion Yes Yes- significantly more than sitagliptin P = 0.0017*
Reduction in post -prandial glucagon Yes Yes- significantly more than sitagliptin P = 0.0011*
Reduction in gastric emptying none Yes- significantly more than sitagliptin P <0.0001*
Six point SMBG excursions Post breakfast Yes- significantly less than sitagliptin P = 0.0016*
Post lunch Similar to Sitagliptin P = 0.07849
Post dinner Yes- significantly less than sitagliptin P = 0.038*
Reduction in body weight (kg) 0.3+/-0.2 0.8+/-0.2 P = 0.0056*
Decrement in calorie intake none Yes- significantly more than sitagliptin P = 0.0227*
Reduction in post-prandial triglyceride levels yes Yes- significantly more than sitagliptin P = 0.018*
Nausea 12% 34%
Vomiting 3% 24%
*Statistically significant. DDP-4, dipeptidyl peptidase 4; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide 1; PPG, postprandial glucose; SMBG, self-
monitoring blood glucose
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A more recent study comparing both of the above thera-
pies given for eight weeks in patients with T2DM (baseline
hemoglobin A1c (HbA1c) of 8.3 ± 1.0% and body mass
index of 35 ± 5 kg/m2) revealed a reduction in postpran-
dial glucagon secretion and an improvement in a homeos-
tasis model assessment of beta-cell function (HOMA-B)
with exenatide 10 mcg bid as well as sitagliptin 100 mg
daily; however, the improvement was significantly more in
exenatide treated patients compared to the sitagliptin trea-
ted group [32]. Both exenatide and sitagliptin therapies
resulted in an improvement in two-hour PPG, average 24-
hour glucose and the time spent with glucose between 3.9
and 7.8 mmol/L over a 24-hour period. However, exena-
tide therapy was associated with significantly lower two-
hour PPG, average 24-hour glucose and more time spent
with glucose between 3.9 and 7.8 mmol/l (P =<0.05). As
recently observed in other studies, postprandial intact
GLP-1 levels were reduced with exenatide therapy and
increased with sitagliptin. Postprandial glucogon levels
were reduced significantly more by exenatide therapy than
sitagliptin (P =<0.005) [32].
To summarize, there appear to be important mechanistic
differences between exenatide and sitagliptin in these short
term studies. Longer term direct head to head comparative
studies are needed to ascertain the durability and effects of
these differences on the glycemic outcomes. Also, it is
important to ascertain if these differential effects extend to
the other agents in the respective incretin based classes.
Head to head RCTs of GLP-1 agonists and DPP-4
inhibitors
The effect of these physiological differences were studied
in four further randomized studies, each lasting for 24 to
26 weeks with one of them having a further extension
period of 26 weeks (Table 1).
The 1860-Lira-DPP-4 study was an open label parallel
group trial comparing liraglutide (1.8 mg and 1.2 mg)
against sitagliptin (100 mg), all in combination with met-
formin in patients treated with T2DM [33]. Recently, the
outcomes of an open label extension for a further 26
weeks in patients completing the 1860-Lira-DPP-4 study
have been published [34]. Therefore, the 1860-Lira-DPP-4
study comparing liraglutide 1.2 and 1.8 mg with sitagliptin
100 mg is the longest head to head comparative study
between a GLP-1 agonist and DPP-4 inhibitor.
The DURATION 2 (Diabetes Therapy Utilization:
Researching changes in A1c, weight and other factors
Through Intervention with exenatide ONce weekly) and
DURATION 4 trials involved comparison of a recently
approved once weekly preparation of exenatide (Exena-
tide QW 2 mg) against sitagliptin (100 mg/day) [35-37].
The DURATION 4 was a monotherapy study while
the DURATION 2 involved combination therapy with
metformin and also had a third arm involving pioglita-
zone [37]. In the T-emerge 4-trial, taspoglutide, a once
weekly GLP-1 analogue, was compared against sitaglip-
tin in a double-dummy 24 week trial [38]. Taspoglutide
was suspended in the late stages of development due to
concerns regarding hypersensitivity reactions and gastro-
intestinal side effects [39].
Changes in HbA1c
In the 1860-Lira-DPP-4 study, mean baseline HbA1c was
8.4%. A greater reduction in HbA1c was seen with liraglu-
tide 1.2 mg (−1.24%; 95% CI, −1.37 to −1.11) and 1.8 mg
(−1.5%; 95% CI, −1.63 to −1.37) compared with sitagliptin
(−0.9%; 95% CI, −1.03 to −0.77). Estimated mean treat-
ment differences for liraglutide at 1.2 mg and 1.8 mg
doses compared to 100 mg sitagliptin were −0.34% for 1.2
mg (P <0.0001) and −0.6% for 1.8 mg (P =<0.0001). The
reduction of 0.9% in HbA1c with sitagliptin in the 1860-
Lira-DPP-4 study is one of the better results achieved in a
trial with sitagliptin [33].
During the extension phase of the 1860-Lira-DPP-4
study, mean HbA1c improvement with liraglutide 1.8 mg
and 1.2 mg, and sitagliptin at 52 weeks from baseline was
1.29%, 1.51% and 0.88%, respectively. Thus liraglutide pro-
duced a significant and sustained reduction in HbA1c
compared to sitagliptin at 52 weeks. The improvement in
glycemic control with liraglutide was irrespective of base-
line HbA1c [34].
In the DURATION-2 study, the mean baseline HbA1c
was 8.6%. Exenatide QW therapy resulted in a significant
reduction in HbA1c compared with sitagliptin (−1.5% ver-
sus −0.9%, P =<0.0001). Significant HbA1c improvement
was noted within four weeks of exenatide QW therapy
and within six weeks of sitagliptin therapy. In a subgroup
of patients with a basal HbA1c less than 9%, exenatide
QW therapy resulted in significant improvements (mean
baseline HbA1c 7.8%, change in HbA1c -1.1%) in compar-
ison to sitagliptin (mean baseline HbA1c 7.7%, change in
HbA1c -0.5%) [35]. It is well appreciated that the relative
contribution of PPG in overall diurnal hyperglycemia is
higher in well controlled subjects with diabetes [40].
Further improvement in HbA1c in a subgroup of well
controlled patients during the DURATION-2 study there-
fore suggests underlying improvements in PPG, although
PPG was not measured in the study.
In the T-emerge 4 Trial, taspoglutide 10 mg and 20 mg
has been shown to improve HbA1c significantly more
than that achieved with sitagliptin (-1.3%, -1.23% and
-0.89% improvement from baseline with taspoglutide 20
mg, 10 mg and sitagliptin, respectively; P <0.001 for both
doses of taspoglutide against sitagliptin). The mean base-
line HbA1c across the treatment arms ranged from 7.95%
to 8.03% in this study [38].
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In the DURATION-4 trial 26 weeks monotherapy with
exenatide QW reduced HbA1c by 1.5% from baseline as
opposed to a 1.2% reduction with sitagliptin [37].
Changes in glucose levels
In the 1860-Lira-DPP-4 study, the mean reduction in FPG
was greater with liraglutide compared to sitagliptin (mean
of -2.14 mmol/L with liraglutide 1.8 mg, -1.87 mmo/L with
liraglutide 1.2 mg and -0.83 mmol/L with sitagliptin 100
mg) [33]. Improvements and differences in FPG were sus-
tained during the extension phase of the 1860-Lira-DPP-4
study. At 52 weeks, the mean reduction in FPG was -2.04
mmol/l, -1.71 mmol/l and -0.59 mmol/l with liraglutide 1.8
mg, 1.2 mg and sitagliptin 100 mg, respectively [34]. Treat-
ment differences between sitagliptin and liraglutide
remained statistically significant for both doses (P <0.0001).
The improvement in mean FPG was twofold greater with
exenatide QW treated patients in comparison to sitagliptin
treated patients in the DURATION-2 trial (-1.8 mmol/L
versus -0.9 mmol/L, respectively) [35]. Changes in PPG
levels were not assessed in these head to head trials. In
contrast to short term mechanistic studies, there was a
significant difference in FPG in these head to head com-
parative trials conducted over a longer period of time.
Differences in efficacy and tolerability among studied GLP-
1 analogue and DPP-4 inhibitor in the 1860-Lira-DPP-4
and DURATION-2 study are summarized in Table 3. In
the DURATION 4 trial exenatide QW significantly
reduced fasting glucose at 16 and 26 weeks as well 7 point
self-monitoring blood glucose (SMBG) profiles compared
to sitagliptin [37].
Changes in body weight
In the 1860-Lira-DPP-4 study group trial, the mean weight
loss was significantly greater with liraglutide than sitaglip-
tin. The estimated mean weight differences were -2.4 kg
(95% CI-3.14 to -1.70) for 1.8 mg liraglutide versus sita-
gliptin, and -1.90 kg (-2.61 to -1.18) for 1.2 mg liraglutide
versus sitagliptin. Liraglutide at both doses produced a
greater reduction in waist circumference but there were
no differences in waist to hip ratio [33]. During the 1860-
Lira DPP4 extension phase, weight loss achieved during
the first 26 weeks was sustained at 52 weeks. At the end of
the study period mean weight loss with liraglutide 1.8 mg,
1.2 mg and sitagliptin was 3.68 kg, 2.78 kg and 1.16 kg,
respectively with mean treatment differences between the
agents remaining statistically significant (P <0.0001) [34].
In the DURATION 2 trial, the differences in weight
loss became apparent by 4 weeks and by week 26, weight
loss with exenatide QW (-2.3 kg, 95% CI -2.9 to -1.7) was
significantly greater compared to sitagliptin (-0.8 kg, 95%
CI -1.4 to -0.1). The mean treatment difference was -1.5
kg (95% CI -2.4 to -0.7, adjusted P = 0.0002) for exena-
tide QW versus sitagliptin. In terms of absolute numbers,
more than 75% (n = 123) of patients on once weekly exe-
natide lost bodyweight compared with 61% (n = 101) of
those on sitagliptin [35]. Weight loss with taspoglutide
10 mg and 20 mg once weekly dose was 1.23 kg and 2.54
kg, respectively, in comparison to 0.55 kg weight loss
seen with sitagliptin over the 24 week study period [38].
In the DURATION 4 trial, treatment with exenatide QW
reduced body weight significantly compared to sitagliptin
(weight loss 2 kg versus 0.8 kg, P =<0.001) [37].
The effect of differential calorie intake and the reduced
gastric emptying noticed during short term mechanistic
studies between agents in the GLP-1 analogue and DPP-
4 inhibitors groups probably explain the differential
weight loss in favor of GLP-1 agonists in the subsequent
longer term head to head comparisons up to a one-year
period.
Changes in blood pressure and other metabolic
parameters
There was no significant difference observed for systolic
blood pressure in the 1860-Lira-DPP-4 study group trial
although both liraglutide and sitagliptin reduced the systo-
lic blood pressure. Sitagliptin reduced diastolic blood pres-
sure significantly compared to 1.8 mg liraglutide but there
was no significant difference compared to 1.2 mg liraglu-
tide. The overall effect on the blood pressure with either
drug was small [33]. During the 1860-Lira-DPP-4 study
extension there were no significant differences noted with
liraglitide or sitaglipin except reduction of systolic blood
pressure with 1.8 mg liraglutide. Other large clinical stu-
dies with liraglutide have shown consistent reductions in
systolic blood pressure [41-46]. During the DURATION-2
trial the exenatide QW treated group had significantly
lower systolic blood pressure at 26 weeks compared to
sitagliptin. The mean difference was -4 mm Hg (CI -6 to
-1 mm of Hg) between once a week exenatide and daily
sitagliptin. There were no significant differences in the
levels of diastolic blood pressure [35]. Similar to liraglu-
tide, large clinical trials with exenatide have shown favor-
able effects on blood pressure [47]. DPP-4 inhibitors, on
the other hand, have shown variable effects on blood pres-
sure [48-50].
The 1860-Lira-DPP-4 study did not observe any signifi-
cant differences with lipid profile except a significant
reduction in total cholesterol from baseline with the 1.8
mg liraglutide dose compared to sitagliptin. In the DURA-
TION 2 trial neither exenatide nor sitagliptin had any sig-
nificant effect on the lipid profile.
Hypoglycemia
In the DURATION-2 trial there were no reported major
hypoglycemic episodes. Minor hypoglycemia episodes were
similar with the exenatide QW and sitagliptin [35]. The
1860-Lira-DPP-4 study reported a single episode of major
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hypoglycemia with 1.2 mg liraglutide (blood glucose con-
centration of 3.6 mmol/L). Minor hypoglycemia episodes
were reported by similar proportions of participants treated
with 1.8 mg liraglutide (11 (5%), 0.370 episodes per partici-
pant-year), 1.2 mg liraglutide (12 (5%), 0.178), and sitaglip-
tin (10 (5%), 0.106) [33]. During the extension phase of the
1860-Lira DPP4 study, no episodes of major hypoglycemia
occurred and the minor hypoglycemia events remained
comparable during the whole 52-week study period [34].
The DURATION 4 trial did not report any major hypogly-
cemia episodes. An incidence of 5.2% in the exenatide QW
group versus 3.1% in the sitagliptin group was reported for
unconfirmed hypoglycemia [51].
Gastrointestinal side effects
As noticed in short term mechanistic studies, all the
longer term comparative RCTs showed more initial nausea
and vomiting with GLP-1 agonists compared to DPP-4
inhibitors. In the 1860-Lira-DPP-4 study, nausea was
more common with liraglutide (21% to 27%) than with
sitagliptin (5%) at the beginning of the therapy but by the
end of the trial, symptoms decreased to the level observed
with sitagliptin (<3%) and patients reported that nausea
remained comparable during the extension period [33,34].
In the DURATION-2 trial nausea was more common with
once a week exenatide (24% patients) compared to sita-
gliptin (10% patients) [36]. The DURATION 4 trial
reported 11.3% patients experiencing nausea on treatment
with exenatide QW while vomiting was noted in 4.8%
patients treated with exenatide QW compared to 1.8%
patients in the siatgliptin group [51].
Incretins and safety
Cases of pancreatitis have been reported in the patients
who were treated with agents in both classes of incretin-
based therapies [52]. During the head to head compari-
son trials, no episode of pancreatitis was noticed during
the first 26 weeks of the 1860-Lira-DPP4 study. However,
an episode of mild non acute pancreatitis was reported
during the extension period [34]. No cases of pancreatitis
were reported during the DURATION-2 trial.
Large preclinical studies involving diabetic mice and rats
have failed to show an association between GLP-1 ago-
nists, such as exenatide and liraglutide, as well as the DPP-
4 inhibitor sitagliptin and pancreatitis [53,54]. Large
cohort studies looking at the health care databases have
not shown any association with the incretin-based thera-
pies and pancreatitis [55,56]. A recently published large
cohort study analyzed the rates of acute pancreatitis in
diabetic subjects treated with exenatide, sitagliptin and
Table 3 Comparison of GLP-1 analogues in DPP-4 inhibitors- data from fully published RCTs [33-35,37].
Study The 1860- Lira DPP-4 study (52 weeks) DURATION 2 (26 weeks) -
Add on therapy to Metformin


















Number of patients 225 221 219 160 166 248 163
Mean baseline HbA1c (%) 8.4 (0.8) 8.4 (0.7) 8.5 (0.7) 8.6 (1.2) 8.5 (1.2) 8.4-8.6 8.4-8.6
Change in HbA1c (%) -1.51 -1.29 -0.88 -1.5 -0.9 -1.53 -1.15
(P =<0.001)
Mean treatment difference in










10.1 (2.4) 9.9(2.4) 10.0 (2.0) 9.2(2.9) 9.1(2.5) 9.7 to 9.9 9.7 to 9.9
Change in FPG
(mmol/L)
-2.04 -1.71 -0.59 -1.8 -0.9 -2.3 -1.1
(P =<0.001)
Mean treatment difference in








Baseline weight (Kg) 93.7(18.4) 94.6(18.1) 93.1(18.9) 89(20) 87(20) 85.9 to 88.6 85.9 to 88.6
Change in weight (Kg) -3.68 -2.78 -1.16 -2.3 -0.8 -2.0 -0.8
(P <0.001)
Mean treatment differences

















1% 3% 5.2% 3.1%
Nausea Number (%) 60 (27.5) 40 (21.7) 12 (5.5) 38 (24) 16 (10) 11.3% 3.7%
Diarrhea Number (%) 27 (12.4) 20 (9) 14 (6.4) 29 (18) 16 (10) 10.9% 5.5%
DDP-4, dipeptidyl peptidase 4; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide 1; HbA1c, hemoglobulin A1c
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other antidiabetic agents using data from the Medco
National Integrated Database from January 2007 to June
2009. The risk of pancreatitis was high in patients with
diabetes compared to patients without diabetes (adjusted
hazard ratio 2.1 (95% CI 1.7 to 2.5)), but there was no
increased risk of pancreatitis seen in patients treated with
exenatide or sitagliptin compared to patients who received
other diabetic medications [57]. The available data do not
support an association between incretin therapies and
pancreatitis. Long term larger studies are needed to inves-
tigate this further.
Long term exposure to liraglutide has been shown to
be associated with thyroid ‘C’ cell hyperplasia in rodents
[58]. In contrast, monkeys and humans have much lower
levels of GLP-1R expression, and prolonged administra-
tion of liraglutide at very high doses has not been shown
to produce C-cell proliferation in monkeys. Data from
long term studies, such as the 1860-Lira-DPP-4 trial,
have not shown any increase in the mean calcitonin level,
which is the marker of C cell hyperplasia and medullary
thyroid carcinoma, in patients treated with liraglutide
[33,59].
Cardiovascular safety
The large ongoing outcome trial LEADER (Liraglutide
Effects and Actions in Diabetes, Evaluation of Cardiovas-
cular Results) will investigate the safety profile of liraglu-
tide in approximately 9,000 patients with T2DM. It will
include patients with a high risk cardiovascular profile in a
global setting [60]. EXSCEL (Exenatide Study of Cardio-
vascular Event Lowering) is a similar large study planned
to investigate the safety of exenatideQW preparations.
EXSCEL is a double-blind randomized, placebo controlled,
multi-national superiority trial in patients with T2DM. It
aims to compare the impact of including exenatide as part
of usual care versus usual care without exenatide on major
cardiovascular outcomes. A total of 9,500 patients will be
recruited and will be followed for a minimum of four
years [61]. TECOS (Trial Evaluating Cardiovascular Out-
comes with Sitalgliptin) hopes to investigate safety and
cardiovascular outcomes with sitagliptin. TECOS is a dou-
ble-blind randomized, placebo controlled, multi-national
trial in patients with T2DM. TECOS aims to compare the
impact of adding sitagliptin as part of usual care versus
usual care without sitagliptin on cardiovascular outcomes.
A total of 14,000 patients will be followed for a minimum
of three years [61].
Patient reported outcome measures and satisfaction
Diabetes mellitus, its treatment and its complications often
affect a patient’s quality of life [8]. Patient reported treat-
ment outcomes may provide the data on health related
quality of life as well information on patients’ perceptions
on efficacy, tolerability and preferences about a particular
therapy. Higher patient satisfaction may indicate better
compliance with the therapy [62-64].
In the 1860-Lira-DPP-4 study group open label trial,
patients’ treatment satisfaction was assessed using the
Diabetes Treatment Satisfaction Questionnaire (DTSQ).
The increase in patients’ treatment satisfaction from base-
line was significantly higher with 1.8 mg liraglutide than
with sitagliptin (4.35 versus 2.96, P = 0.03), but the
increase with 1.2 mg liraglutide versus sitagliptin was not
significant. Patients reported significantly greater improve-
ment in treatment satisfaction with liraglutide 1.8 mg than
sitagliptin on three items: ‘current treatment’ (difference =
0.35; P = 0.01), ‘recommend’ (difference = 0.41; P = 0.003)
and ‘continue’ (difference = 0.44; P = 0.01). Patients per-
ceived themselves less hyperglycemic on either of the
doses of liraglutide compared to sitagliptin (P <0.05).
There was no difference between liraglutide and sitagliptin
on DTSQ items relating to treatment convenience and
flexibility, indicating that patients were no less satisfied
with the injectable than with the oral agent [65].
There was no significant difference in all five domains of
the IWQOL total score between exenatide once a weekly
and sitagliptin (5.15 versus 4.56). A greater improvement
in overall treatment satisfaction was recorded with exena-
tide than with sitagliptin (difference 1.61, P = 0.0406).
However, the DURATION 2 was a double dummy trial
with all of the patients receiving a tablet as well as an
injection. Hence, it is more difficult to tease out the differ-
ences between therapies [35].
In the double blind placebo controlled DURATION 4
trial there was no significant difference in weight-related
quality of life, binge-eating behavior or health status
between exenatide QW and sitagliptin monotherapy.
Conclusions
In the clinical trials, both types of incretin-based therapies
are effective in improving hyperglycemia; however, as sug-
gested by the proof of concept study, the magnitude of
glycemic improvement was significantly higher with GLP-
1R agonists and was consistent in the order of estimated
mean treatment difference in HbA1c of 0.34% to 0.63%
over and above that obtained with DPP-4 inhibitors.
Greater HbA1c reduction with GLP-1agonists is probably
due to pharmacological concentrations of free (non-albu-
min-bound) GLP-1 agonists [31,66]. DPP-4 inhibitors
achieve two to three times increment in the native GLP
concentration. However, several fold higher levels of GLP-
1 agonist leads to greater stimulation of GLP-1 receptor
[66]. Similarly, there is also a significantly greater weight
loss (estimated mean treatment difference of -1.5 to -2.53
Kg) associated with GLP-1 agonists compared to DPP-4
inhibitors. This is most likely due to reduced calorie intake
and central satiety effects. Although the differences in FPG
were not evident during the initial short term proof of
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concept study, the longer term RCTs have consistently
shown greater improvements in FPG with GLP-1 agonists
as compared to DPP-4 inhibitors. Sitagliptin has a similar
pharmacokinetic half-life to liraglutide (about 12 hours)
but the increase in endogenous GLP-1 concentrations
with DPP-4 inhibitors occurs mainly after meals. Thus,
fasting concentrations of active GLP-1 remain fairly low
overnight, so reductions in FPG concentrations with sita-
gliptin are low compared with liraglutide. While GLP-1
agonists are injected, DPP-4 inhibitors are taken orally
and, although it is often stated that patients resist inject-
able therapies, published data suggest this is not by any
means a universal finding. The results from the open label
1860 trial with liraglutide suggest patients were no less
satisfied with injectable therapy compared to oral DPP-4
inhibitors and, in fact, were more satisfied in the 1.8 mg
liraglutide arm compared to sitagliptin [65].
In general, the efficacy and safety of the incretin based
agents from both classes have been shown to be durable.
Their safety with longer term use will be ascertained by
currently ongoing outcome trials (LEADER, EXSCEL, and
TECOS) [60,61].
Similarly, although the currently marketed DPP-4 inhibi-
tors appear to be comparable as a class regarding the
degree of glycemic improvement, only sitagliptin was
tested in these direct head to head comparisons. However,
sitagliptin is the most widely prescribed DPP-4 inhibitor.
As with the other therapies, the selection of an incretin
based agent for glycemic control in patients with T2DM
should be individualized, taking into consideration the
aims and intensity of glycemic improvement, tolerability
of the therapy, the effect of such therapy on the various
co-existing morbidities while assuring the therapy is
acceptable and safe for patients in the longer term.
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